BACtrack's Keith Nothacker tells CNBC how he saw an opportunity to create a wearable device to monitor alocohol levels. » Read More
Ansell MD and CEO Magnus Nicolin expects topline growth of 2 to 4 percent in the medium-term, driven by its industrial business. » Read More
suitX's Homayoon Kazerooni explains how Phoenix, a robotic suit, helps people suffering from mobility issues such as spinal cord injuries. » Read More
The White House said the bill "falls far short" of the necessary funding, but Obama would sign it "because some action is better than none."
HeartWare stock soared more than 90 percent on news that the company will be acquired by Medtronic.
The popular, needle-free FluMist influenza vaccine should not be used this coming flu season, experts said Wednesday, NBC News reports.
PX90 creator Tony Horton offers his perspective on fitness after 40.
A new device that drains a portion of a person's stomach contents after every meal, has just won approval from the U.S. Food and Drug Administration.
These professors point out some "glaring errors" in the attack on Bernie Sanders' single-payer health plan.
It's been a brutal year for Valeant, and one trader is betting the bad news is about to get much worse for the drug company's stock.
Is the biotech industry having a good year or a slow one? Expert analysts weigh in on CNBC's "Power Lunch."
Zika shouldn't have caught us by surprise, writes Dr. Claire Pomeroy. Here's what needs to be done to prevent the next killer virus.
"Maude" creator Norman Lear can't believe a woman’s right to choose is still under fire. It has a huge impact on their lives and careers.
A co-author of the study that found variability in Theranos medical tests said they plan to make their protocols public.
The cosmetic medical procedure is gaining favor among both men and women.
Benzhong Tang from Hong Kong University of Science and Technology, explains how he developed an AIE fluorescent material dyes cancer cells, making them easier to track.
Ulrich Spiesshofer, CEO of ABB, says his company needs to readjust its efforts, especially in China where sluggish demand hit profits.
Researchers are testing way to detect the presence of the disease in almost all types of cancer mutations.
The recent criticism surrounding $9 billion diagnostics firm Theranos has been unfair, Theranos board member Richard Kovacevich tells CNBC.
Get the best of CNBC in your inbox